loading page

DPP-4 inhibitors in the prevention/treatment of multi-organ injury caused by COVID-19 - a therapeutic approach of choice in type 2 diabetic patients?
  • +4
  • Andrija Šmelcerović,
  • Gordana Kocić,
  • Mihajlo Gajić,
  • Katarina Tomović,
  • Vukica Đorđević,
  • Dobrila Stanković Đorđević,
  • Marko Anderluh
Andrija Šmelcerović
University of Nis Faculty of Medicine
Author Profile
Gordana Kocić
University of Nis Faculty of Medicine
Author Profile
Mihajlo Gajić
Medicinal Faculty, University of Nis
Author Profile
Katarina Tomović
University of Nis Faculty of Medicine
Author Profile
Vukica Đorđević
University of Nis Faculty of Medicine
Author Profile
Dobrila Stanković Đorđević
University of Nis Faculty of Medicine
Author Profile
Marko Anderluh
Faculty of Pharmacy University of Ljubljana
Author Profile

Abstract

Since the outbreak of SARS-CoV-2 virus more than 2 800 000 cases have been reported worldwide. Patients suffering from diabetes and other comorbidities are particularly susceptible to severe forms of the COVID-19, which might result in chronic complications following recovery. Dipeptidyl peptidase-4 inhibitors exert beneficial effects in the prevention/treatment of pulmonary fibrosis, heart, and kidney injury, and since they may be a long-term consequence caused by COVID-19, it is reasonable to expect that DPP-4 inhibitors might be beneficial in alleviating long-term consequences of COVID-19. With that in mind, we would like to voice our concerns over chronic implications following recovery from COVID-19 especially in diabetic, but also in non-diabetic patients, and to indicate that some preventive measures could be undertaken by application of DPP-4 inhibitors.